VR Adviser’s 4D Molecular Therapeutics FDMT Stock Holding History

VR Adviser’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-677,600	Closed	-$2.19M	–	33
2025 Q1	$2.19M	Sell	677,600 -2,274,771	-77%	-$10.7M	0.19%	30
2024 Q4	$16.4M	Sell	2,952,371 -1,447,629	-33%	-$11.4M	1.13%	21
2024 Q3	$47.6M	Hold	4,400,000	–	–	2.49%	13
2024 Q2	$92.4M	Hold	4,400,000	–	–	5.88%	3
2024 Q1	$140M	Buy	4,400,000 +975,969	+29%	+$24.9M	6.67%	2
2023 Q4	$69.4M	Buy	3,424,031 +424,031	+14%	+$5.58M	4.76%	5
2023 Q3	$38.2M	Hold	3,000,000	–	–	4.02%	8
2023 Q2	$54.2M	Buy	+3,000,000	New	+$55.2M	8.67%	3

Other funds holding FDMT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser's FDMT Position: Q2 2025 in Review

VR Adviser sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 677,600 shares — an estimated $2.19M sold.

VR Adviser first reported a position in FDMT in Q2 2023 and held it in 8 quarters. The position peaked at $140M in Q1 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

VR Adviser reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
VR Adviser sold 677,600 4D Molecular Therapeutics shares in Q2 2025, an estimated $2.19M.
VR Adviser first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 8 quarters.
VR Adviser's 4D Molecular Therapeutics position peaked at $140M in Q1 2024.
120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on VR Adviser's 13F filing for Q2 2025, filed 14 Aug 2025.